Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note published on Wednesday. The firm issued a sell rating on the stock.

MBRX has been the subject of a number of other reports. Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Moleculin Biotech in a research report on Monday, March 3rd.

Moleculin Biotech Stock Up 1.8 %

Shares of NASDAQ MBRX opened at $1.12 on Wednesday. The business has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $2.12. Moleculin Biotech has a twelve month low of $0.40 and a twelve month high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.